Literature DB >> 24326163

Cortical synaptic NMDA receptor deficits in α7 nicotinic acetylcholine receptor gene deletion models: implications for neuropsychiatric diseases.

Hong Lin1, Fu-Chun Hsu1, Bailey H Baumann1, Douglas A Coulter2, David R Lynch3.   

Abstract

Microdeletion of the human CHRNA7 gene (α7 nicotinic acetylcholine receptor, nAChR) as well as dysfunction in N-methyl-d-aspartate receptors (NMDARs) have been associated with cortical dysfunction in a broad spectrum of neurodevelopmental and neuropsychiatric disorders including schizophrenia. However, the pathophysiological roles of synaptic vs. extrasynaptic NMDARs and their interactions with α7 nAChRs in cortical dysfunction remain largely uncharacterized. Using a combination of in vivo and in vitro models, we demonstrate that α7 nAChR gene deletion leads to specific loss of synaptic NMDARs and their coagonist, d-serine, as well as glutamatergic synaptic deficits in mouse cortex. α7 nAChR null mice had decreased cortical NMDAR expression and glutamatergic synapse formation during postnatal development. Similar reductions in NMDAR expression and glutamatergic synapse formation were revealed in cortical cultures lacking α7 nAChRs. Interestingly, synaptic, but not extrasynaptic, NMDAR currents were specifically diminished in cultured cortical pyramidal neurons as well as in acute prefrontal cortical slices of α7 nAChR null mice. Moreover, d-serine responsive synaptic NMDAR-mediated currents and levels of the d-serine synthetic enzyme serine racemase were both reduced in α7 nAChR null cortical pyramidal neurons. Our findings thus identify specific loss of synaptic NMDARs and their coagonist, d-serine, as well as glutamatergic synaptic deficits in α7 nAChR gene deletion models of cortical dysfunction, thereby implicating α7 nAChR-mediated control of synaptic NMDARs and serine racemase/d-serine pathways in cortical dysfunction underlying many neuropsychiatric and neurodevelopmental disorders, particularly those associated with deletion of human CHRNA7.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cortex; Extrasynaptic NMDA receptor; Glutamatergic synaptic deficits; N-methyl-d-aspartate receptor; NMDAR; Neuropsychiatric diseases; SR; Schizophrenia; Serine racemase; Synaptic NMDA receptor; VGLUT1; WT; d-serine; nAChR; nicotinic acetylcholine receptor; serine racemase; vesicular glutamate transporter 1; wild-type; α7 nAChR null; α7 nicotinic acetylcholine receptor; α7-KO

Mesh:

Substances:

Year:  2013        PMID: 24326163      PMCID: PMC3915878          DOI: 10.1016/j.nbd.2013.11.021

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  61 in total

1.  NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory.

Authors:  Tatiana Korotkova; Elke C Fuchs; Alexey Ponomarenko; Jakob von Engelhardt; Hannah Monyer
Journal:  Neuron       Date:  2010-11-04       Impact factor: 17.173

2.  Role of the NR2A/2B subunits of the N-methyl-D-aspartate receptor in glutamate-induced glutamic acid decarboxylase alteration in cortical GABAergic neurons in vitro.

Authors:  H Monnerie; F-C Hsu; D A Coulter; P D Le Roux
Journal:  Neuroscience       Date:  2010-10-20       Impact factor: 3.590

3.  Homozygous deletion of chromosome 15q13.3 including CHRNA7 causes severe mental retardation, seizures, muscular hypotonia, and the loss of KLF13 and TRPM1 potentially cause macrocytosis and congenital retinal dysfunction in siblings.

Authors:  Malte Spielmann; Gabriele Reichelt; Christoph Hertzberg; Marc Trimborn; Stefan Mundlos; Denise Horn; Eva Klopocki
Journal:  Eur J Med Genet       Date:  2011-04-29       Impact factor: 2.708

4.  NMDA receptor and schizophrenia: a brief history.

Authors:  Joseph T Coyle
Journal:  Schizophr Bull       Date:  2012-09       Impact factor: 9.306

Review 5.  Diversity in NMDA receptor composition: many regulators, many consequences.

Authors:  Antonio Sanz-Clemente; Roger A Nicoll; Katherine W Roche
Journal:  Neuroscientist       Date:  2012-02-17       Impact factor: 7.519

Review 6.  Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease.

Authors:  Tanya L Wallace; Richard H P Porter
Journal:  Biochem Pharmacol       Date:  2011-07-02       Impact factor: 5.858

7.  Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission.

Authors:  H Wolosker; S Blackshaw; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

8.  Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors.

Authors:  R Girod; N Barazangi; D McGehee; L W Role
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

9.  Twenty-five years of glutamate in schizophrenia: are we there yet?

Authors:  Daniel C Javitt
Journal:  Schizophr Bull       Date:  2012-09       Impact factor: 9.306

10.  Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion.

Authors:  T M Ma; S Abazyan; B Abazyan; J Nomura; C Yang; S Seshadri; A Sawa; S H Snyder; M V Pletnikov
Journal:  Mol Psychiatry       Date:  2012-07-17       Impact factor: 15.992

View more
  30 in total

1.  Neuronal serine racemase associates with Disrupted-In-Schizophrenia-1 and DISC1 agglomerates: Implications for schizophrenia.

Authors:  Ariel A Jacobi; Sarah Halawani; David R Lynch; Hong Lin
Journal:  Neurosci Lett       Date:  2018-11-01       Impact factor: 3.046

2.  Cortical parvalbumin GABAergic deficits with α7 nicotinic acetylcholine receptor deletion: implications for schizophrenia.

Authors:  Hong Lin; Fu-Chun Hsu; Bailey H Baumann; Douglas A Coulter; Stewart A Anderson; David R Lynch
Journal:  Mol Cell Neurosci       Date:  2014-06-28       Impact factor: 4.314

3.  Nicotinic acetylcholine receptor subunit α7-knockout mice exhibit degraded auditory temporal processing.

Authors:  Richard A Felix; Vicente A Chavez; Dyana M Novicio; Barbara J Morley; Christine V Portfors
Journal:  J Neurophysiol       Date:  2019-05-22       Impact factor: 2.714

4.  Activation of alpha7 nicotinic and NMDA receptors is necessary for performance in a working memory task.

Authors:  David Phenis; Sarah A Vunck; Valentina Valentini; Hugo Arias; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2020-03-11       Impact factor: 4.530

5.  Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness.

Authors:  Thomas Papouin; Jaclyn M Dunphy; Michaela Tolman; Kelly T Dineley; Philip G Haydon
Journal:  Neuron       Date:  2017-05-04       Impact factor: 17.173

Review 6.  Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia.

Authors:  Daniel C Javitt; Robert Freedman
Journal:  Am J Psychiatry       Date:  2014-11-17       Impact factor: 18.112

7.  Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding.

Authors:  Michelle L Pershing; David Phenis; Valentina Valentini; Ana Pocivavsek; Derick H Lindquist; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2016-08-16       Impact factor: 4.530

8.  Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.

Authors:  Daniel C Javitt
Journal:  Curr Treat Options Psychiatry       Date:  2015-06

Review 9.  The involvement of N-methyl-D-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia.

Authors:  Peijun Ju; Donghong Cui
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-02-01       Impact factor: 3.848

10.  Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders.

Authors:  Sophie Erhardt; Ana Pocivavsek; Mariaelena Repici; Xi-Cong Liu; Sophie Imbeault; Daniel C Maddison; Marian A R Thomas; Joshua L Smalley; Markus K Larsson; Paul J Muchowski; Flaviano Giorgini; Robert Schwarcz
Journal:  Biol Psychiatry       Date:  2016-12-16       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.